Introduction

308nm excimer therapy is a targeted ultraviolet B (UVB) phototherapy used primarily in dermatology for localized inflammatory and autoimmune skin diseases.

It is most commonly indicated for vitiligo and psoriasis, where it delivers monochromatic UVB light directly to affected lesions while minimizing exposure to surrounding healthy skin.

This article reviews the biological mechanism, clinical evidence, treatment protocols, and safety profile of 308nm excimer therapy based on peer-reviewed dermatology literature and international clinical guidelines.

1. What Is 308nm Excimer Therapy?

308nm excimer therapy uses monochromatic UVB light at a wavelength of 308 nanometers. This wavelength lies within the therapeutic range of narrowband UVB (NB-UVB) phototherapy but is delivered in a targeted manner.

Unlike whole-body narrowband UVB cabinets, excimer devices focus high-energy UVB light only on diseased skin areas.

This targeted approach allows:

• Higher fluence delivery per session

• Reduced cumulative UV exposure

• Faster repigmentation in localized vitiligo

• Rapid plaque resolution in localized psoriasis

According to the American Academy of Dermatology (AAD), excimer laser therapy is particularly useful for localized vitiligo involving less than 10% body surface area [1].

2. Mechanism of Action

2.1 In Vitiligo

Vitiligo is characterized by autoimmune destruction of melanocytes.

308nm UVB works through:

1. Local immunosuppression of autoreactive T lymphocytes

2. Induction of T-cell apoptosis

3. Stimulation of residual melanocytes in hair follicles

4. Promotion of melanocyte migration and proliferation

Studies show that excimer therapy induces apoptosis of pathogenic T-cells and increases melanocyte-stimulating cytokines in lesional skin [2].

This dual mechanism explains why excimer therapy often produces earlier perifollicular repigmentation compared to topical therapy alone.

2.2 In Psoriasis

Psoriasis is driven by T-cell–mediated inflammation and keratinocyte hyperproliferation.

308nm UVB exerts its therapeutic effects by:

• Inducing apoptosis of activated T cells

• Suppressing pro-inflammatory cytokines (IL-17, IL-23 pathways)

• Reducing keratinocyte proliferation

Clinical phototherapy guidelines from the AAD and National Psoriasis Foundation confirm targeted UVB therapy as an effective option for localized plaque psoriasis [3].

3. Clinical Evidence and Efficacy

3.1 Vitiligo Outcomes

Multiple studies demonstrate significant repigmentation rates in localized vitiligo.

• Facial lesions show the highest response rates

• Early intervention improves outcomes

• Combination therapy (topical corticosteroids or calcineurin inhibitors + excimer) enhances efficacy

A systematic review published in the British Journal of Dermatology reported that excimer therapy achieves ≥50% repigmentation in a substantial proportion of localized vitiligo patients, particularly on the face and neck [2].

3.2 Psoriasis Outcomes

For localized plaque psoriasis:

• Clearance often occurs within 10–20 sessions

• High fluence protocols reduce treatment duration

• Targeted therapy minimizes systemic exposure

The Joint AAD–NPF phototherapy guidelines state that excimer laser therapy is effective for stable plaque psoriasis and can produce faster lesion clearance compared to conventional NB-UVB in selected patients [3].

4. Treatment Protocols

Treatment parameters vary depending on disease type and skin phototype.

Common protocol features include:

• 2–3 sessions per week

• Gradual dose escalation

• Initial dosing based on minimal erythema dose (MED)

• Monitoring for erythema or blistering

Localized lesions generally require fewer sessions compared to whole-body NB-UVB.

In clinical settings, 308nm therapy is delivered using handheld or stationary excimer systems designed for targeted UVB emission.

5. Safety Profile

308nm excimer therapy is generally well tolerated.

Common transient side effects include:

• Mild erythema

• Localized blistering (dose-dependent)

• Temporary hyperpigmentation

Unlike systemic immunosuppressants, excimer therapy does not produce systemic adverse effects.

Long-term carcinogenic risk appears low when used appropriately, although cumulative UV exposure should be monitored according to established phototherapy safety standards [4].

6. 308nm Excimer vs Narrowband UVB: Key Differences

Targeted delivery makes excimer therapy particularly advantageous for small-area disease.

7. Which Patients Benefit Most?

According to dermatology guidelines, ideal candidates include:

• Localized vitiligo (<10% BSA)

• Stable plaque psoriasis

• Patients unresponsive to topical therapy

• Patients unsuitable for systemic treatments

Clinical decision-making should always consider disease extent, phototype, and treatment history.

For localized treatment delivery, dedicated 308nm targeted phototherapy systems are commonly used in dermatology clinics.

8. Frequently Asked Questions (FAQ)

1. Is 308nm excimer therapy effective for vitiligo?

Yes. Clinical studies and dermatology guidelines support the use of 308nm excimer therapy for localized vitiligo, particularly involving less than 10% body surface area [1][2].

Response rates are highest for:

• Facial lesions

• Recent-onset vitiligo

• Combination therapy with topical corticosteroids or calcineurin inhibitors

Perifollicular repigmentation is commonly observed after multiple sessions.

2. How long does it take to see results from 308nm excimer therapy?

Initial signs of repigmentation in vitiligo or plaque thinning in psoriasis are often observed after 4–8 sessions.

However, optimal outcomes typically require:

• 10–20 treatment sessions

• 2–3 sessions per week

• Dose escalation based on skin response

Individual response varies depending on disease duration, lesion location, and phototype.

3. Is 308nm excimer therapy safe?

308nm excimer therapy is generally well tolerated when administered according to established phototherapy protocols [3][4].

Common side effects include:

• Mild erythema

• Temporary hyperpigmentation

• Rare localized blistering

Systemic adverse effects are not associated with this treatment modality.

Long-term carcinogenic risk appears low when cumulative UV exposure is appropriately monitored.

4. What is the difference between excimer laser and narrowband UVB?

Both treatments use UVB wavelengths within the therapeutic range.

The key difference lies in delivery:

• Excimer therapy is targeted to lesions only.

• Narrowband UVB cabinets expose larger body areas.

Excimer therapy allows higher fluence per lesion and may lead to faster clearance in localized disease [3].

5. Who is a good candidate for 308nm excimer therapy?

Ideal candidates include:

• Patients with localized vitiligo

• Stable plaque psoriasis

• Individuals unresponsive to topical therapy

• Patients unsuitable for systemic immunosuppressants

Clinical evaluation is necessary to determine treatment suitability.

6. Can 308nm excimer therapy be combined with other treatments?

Yes. Combination therapy is commonly used in clinical practice.

For vitiligo:

• Topical corticosteroids

• Tacrolimus ointment

For psoriasis:

• Topical vitamin D analogs

• Topical corticosteroids

Combination regimens may enhance therapeutic response [2][3].

Conclusion

308nm excimer therapy is a clinically validated targeted phototherapy option for vitiligo and psoriasis.

Its mechanism involves selective immunomodulation and stimulation of repigmentation pathways.

Clinical guidelines support its use for localized disease due to its precision, favorable safety profile, and ability to deliver higher therapeutic doses directly to affected skin.

As dermatology continues to shift toward targeted and lesion-specific therapies, 308nm excimer treatment remains an important modality within modern phototherapy practice.

References

[1] American Academy of Dermatology Association. Excimer laser therapy for vitiligo and psoriasis.

[2] Taieb A, et al. Guidelines for the management of vitiligo. British Journal of Dermatology. 2013.

[3] Menter A, et al. Joint AAD–NPF guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology. 2019.

[4] Feldman SR, et al. Phototherapy in psoriasis: An updated clinical review. Journal of the American Academy of Dermatology.